Nature Communications (Jul 2024)

A genetic-epigenetic interplay at 1q21.1 locus underlies CHD1L-mediated vulnerability to primary progressive multiple sclerosis

  • Majid Pahlevan Kakhki,
  • Antonino Giordano,
  • Chiara Starvaggi Cucuzza,
  • Tejaswi Venkata S. Badam,
  • Samudyata Samudyata,
  • Marianne Victoria Lemée,
  • Pernilla Stridh,
  • Asimenia Gkogka,
  • Klementy Shchetynsky,
  • Adil Harroud,
  • Alexandra Gyllenberg,
  • Yun Liu,
  • Sanjaykumar Boddul,
  • Tojo James,
  • Melissa Sorosina,
  • Massimo Filippi,
  • Federica Esposito,
  • Fredrik Wermeling,
  • Mika Gustafsson,
  • Patrizia Casaccia,
  • Jan Hillert,
  • Tomas Olsson,
  • Ingrid Kockum,
  • Carl M. Sellgren,
  • Christelle Golzio,
  • Lara Kular,
  • Maja Jagodic

DOI
https://doi.org/10.1038/s41467-024-50794-z
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Multiple Sclerosis (MS) is a heterogeneous inflammatory and neurodegenerative disease with an unpredictable course towards progressive disability. Treating progressive MS is challenging due to limited insights into the underlying mechanisms. We examined the molecular changes associated with primary progressive MS (PPMS) using a cross-tissue (blood and post-mortem brain) and multilayered data (genetic, epigenetic, transcriptomic) from independent cohorts. In PPMS, we found hypermethylation of the 1q21.1 locus, controlled by PPMS-specific genetic variations and influencing the expression of proximal genes (CHD1L, PRKAB2) in the brain. Evidence from reporter assay and CRISPR/dCas9 experiments supports a causal link between methylation and expression and correlation network analysis further implicates these genes in PPMS brain processes. Knock-down of CHD1L in human iPSC-derived neurons and knock-out of chd1l in zebrafish led to developmental and functional deficits of neurons. Thus, several lines of evidence suggest a distinct genetic-epigenetic-transcriptional interplay in the 1q21.1 locus potentially contributing to PPMS pathogenesis.